Salute e Benessere

Galapagos announces start of Phase 2 study with selective TYK2 inhibitor…

GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor GLPG3667 is currently in development for the treatment of inflammatory and auto-immune diseases and is in Phase 2 for dermatomyositis Mechelen, Belgium; 28 August 2023 , 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient was randomized in GALACELA, a Phase 2 systemic lupus erythematosus (SLE) trial with GLPG3667. The...
Nasdaq GlobeNewswire
28/08/2023

The Recreation Industry is Projected to Experience a 7% Annual Growth Rate from…

Prominent highlights extracted from the Global Market Model's recent forecast for the entertainment and recreation industry, assembled in June 2023, encompass: Prominent highlights extracted from the Global Market Model's recent forecast for the entertainment and recreation industry, assembled inJune 2023, encompass: Gain more insights into the entertainment and recreation industry trends with a free consultation: https://bit.ly/40IIkfq The Global Market Model provides in-depth...
PR Newswire
28/08/2023

Mithra completes EUR 20 million private placement in equity Update of total…

THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW Mithra completes EUR 20 million private placement in equityUpdate of total number of voting rights (denominator)Liege, Belgium, 28 August 2023 – 17:45CEST– Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the "Company" or "Mithra"), a company...
Nasdaq GlobeNewswire
28/08/2023

Pharmaceuticals Industry Overview: Growth Prospects, Influencing Factors, and…

Pharmaceutical industry size and forecast Pharmaceutical industry size and forecast In 2022, the worldwide pharmaceuticals sector achieved a valuation of $1610.7 billion . On an individual basis, per capita consumption within the market amounted to$206. This market segment constituted1.6% of the global Gross Domestic Product (GDP). Anticipated growth in the pharmaceuticals market indicates a compound annual growth rate(CAGR) of 6.8% from 2022 through 2032. This expansion...
PR Newswire
28/08/2023

Dietary Supplements Market size worth USD 239.50 Billion, Globally, by 2030 at…

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=30536 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=30536 Browse in-depth TOCon" Dietary Supplements Market " 202 - Pages 126 – Tables 37 – Figures Explosive Growth Forecasted for the Dietary Supplements Market: A Comprehensive Market Research Analysis The dietary supplements market inJapanis poised for remarkable expansion in the upcoming...
PR Newswire
28/08/2023

Genmab to Present at Morgan Stanley 21st Annual Global Healthcare Conference

Media Release COPENHAGEN, Denmark; August 28, 2023Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan van de Winkel, Ph.D. and Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Morgan Stanley 21 stAnnual Global Healthcare Conference at 3:35 PM EDT / 9:35 PM CEST on September 12, 2023. A webcast of the event, which will include brief opening remarks followed by a question-and-answer session, will be available on...
Nasdaq GlobeNewswire
28/08/2023

Novo Nordisk A/S - share repurchase programme

Bagsværd , Denmark, 28August 2023– On 10 August 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023...
Nasdaq GlobeNewswire
28/08/2023

Navigating the Future of Neurosurgery: Brain Navi demonstrates NaoTrac and…

KrystoLens is the new single-use neuro-endoscope, particularly designed to meet unmet neuro-surgery needs. It has a wide crystal-clear working channel to ensure accuracy in surgical procedures while the single-usage prevents post-surgery infection risk. KrystoLens is the new single-use neuro-endoscope, particularly designed to meet unmet neuro-surgery needs. It has a wide crystal-clear working channel to ensure accuracy in surgical procedures while the single-usage prevents post-surgery...
PR Newswire
28/08/2023

Novartis presents new long-term Leqvio® (inclisiran) data demonstrating…

Results from the ORION-8 open-label extension trial show twice-yearly* Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol (LDL-C) reduction beyond six years of treatment 1 Eight in ten patients achieved target LDL-C threshold**, in line with previously reported Phase III data 1-3 Long-term safety data was consistent with previous findings, confirming the well-established and favorable safety profile of Leqvio 1-3 ...
Nasdaq GlobeNewswire
28/08/2023

Cellares Announces Bristol Myers Squibb has Joined Technology Adoption…

"We're pleased to welcome Bristol Myers Squibb to the TAP program, and we look forward to demonstrating the ease and efficacy of transferring one of BMS's cell therapy process onto the Cell Shuttle in the months to come," said Cellares CEO Fabian Gerlinghaus. "By combining integrated automation with a high-throughput platform, the Cell Shuttle offers unrivaled scalability for the cell therapy industry, while improving quality and lowering COGS." "We're pleased to welcome…
PR Newswire
28/08/2023

Ferinject® granted upgraded recommendations in 2023 ESC heart failure guidelines

ST. GALLEN, Switzerland, Aug. 28, 2023 /PRNewswire/ -- CSL Vifor is pleased to announce that the European Society of Cardiology (ESC) have upgraded recommendations in the ESC 2023 guidelines for the treatment of iron deficiency acute and chronic HF with IV iron supplementation, including Ferinject®. ST. GALLEN,Switzerland,Aug. 28, 2023/PRNewswire/ -- CSL Vifor is pleased to announce that the European Society of Cardiology (ESC) have upgraded recommendations in the ESC 2023 guidelines for...
PR Newswire
28/08/2023

Sobi publishes prospectus regarding the rights issue

A prospectus containing the complete terms and conditions of the rights issue has today, on 28 August 2023, been published on Sobi's website, www.sobi.com/en/rights-issue-2023, and via Danske Bank's website for prospectuses, www.danskebank.se/prospekt. A prospectus containing the complete terms and conditions of the rights issue has today, on28 August 2023, been published on Sobi's website,www.sobi.com/en/rights-issue-2023, and via Danske Bank's website for prospectuses,www.danskebank...
PR Newswire
28/08/2023

Global Heart Hub announces the launch of new patient-led research to bring…

GALWAY, Ireland, Aug. 28, 2023 /PRNewswire/ -- Following the unveiling in 2022 of Global Heart Hub'sGlobal Cholesterol Action Plan, supported by the World Heart Federation, community support has grown to 70 patient organisations and groups who together are calling for global action to reduce the impact of unhealthy cholesterol levels. To reinforce this call to action, Global Heart Hub will begin to collect patient insights from individuals whose cholesterol levels are not at target or those who…
PR Newswire
28/08/2023

3B Scientific acquires iNNOGING Medical

Todd A. Murray, CEO of 3B Scientific, shared: "We're extremely excited to have iNNOGING Medical join our growing 3B Scientific family. Their innovative approach to digitally training ultrasound skills with e Sono is truly impressive. Together, we will work towards revolutionizing the field of sonography training. Our shared goal is to make a profound impact on healthcare education worldwide." Todd A. Murray, CEO of3BScientific,shared : "We're extremely excited to have iNNOGING…
PR Newswire
28/08/2023

XNK Therapeutics to present at the 8th CAR-TCR Summit in Boston

On August 30, Linda Brink will present XNK and talk about improving training and internal collaboration initiatives to address the demand for skilled workers in cell therapy manufacturing. OnAugust 30,Linda Brinkwill present XNK and talk about improving training and internal collaboration initiatives to address the demand for skilled workers in cell therapy manufacturing. For more information, please contact: Johan Liwing, CEO, XNK Therapeutics Tel: +46 706 70 36 75 E-mail:...
PR Newswire
28/08/2023

Mallinckrodt plc Takes Next Step to Implement Comprehensive Financial…

Vendors and Suppliers Expected to be Paid in Full in the Ordinary Course Vendors and Suppliers Expected to be Paid in Full in the Ordinary Course DUBLIN,Aug. 28, 2023/PRNewswire/ --Mallinckrodtplc (NYSE American: MNK) (" Mallinckrodt " or the "Company"), a global specialty pharmaceutical company, today announced that it has taken the next step to implement the comprehensive financial restructuring plan contemplated by a Restructuring Support Agreement ("RSA") the…
PR Newswire
28/08/2023

26th World Congress of the International Federation for the Surgery of Obesity…

The study also showed that women who had surgery had a 47% lower risk of dying from uterine, ovarian, colon, pre-and post-menopausal breast cancer, than women who did not undergo surgery. The study also showed that women who had surgery had a 47% lower risk of dying from uterine, ovarian, colon, pre-and post-menopausal breast cancer, than women who did not undergo surgery. Bariatric surgery results in lower incidence rates of colon cancer too. The advantages of bariatric surgery will be...
PR Newswire
28/08/2023

Sandoz completes acquisition of leading antifungal agent Mycamine® from…

Sandoz completes acquisition of worldwide brand rights for Mycamine®(micafungin sodium) from Astellas Leading global echinocandin, one of three major antifungal classes, will significantly reinforce Sandoz hospital offering and leading anti-infectives portfolioAddition of Mycamine®will support Sandoz drive to ensure responsible use of antimicrobials, through targeted use of most appropriate therapies Basel, August 28, 2023– Sandoz, a global leader in generic and...
Nasdaq GlobeNewswire
28/08/2023

Press Release Biocartis Group NV: Biocartis appoints new Medical Advisory Board…

PRESS RELEASE: 28August2023 , 7:00 AM CEST Biocartis appoints new Medical Advisory Board (MAB) of renowned practice leadersMechelen, Belgium, 28 August 2023- Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), is pleased to announce the appointment of a global Medical Advisory Board (MAB) comprised on renowned and influential KOLs in diagnostics, pharma and hospitals to advise,...
Nasdaq GlobeNewswire
28/08/2023

Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its…

Saint-Herblain (France) , August28 , 2023–ValnevaSE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive initial Phase 3 safety data in adolescents for its single-dose chikungunya virus (CHIKV) vaccine candidate VLA1553. Immunogenicity data for the trial are expected in November 2023.Funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and conducted in collaboration with Instituto Butantan, the VLA1553-321...
Nasdaq GlobeNewswire
28/08/2023

LG HOME APPLIANCES SHOWCASE TOP-RATED ENERGY EFFICIENCY FOR A SUSTAINABLE LIFE…

Energy Efficient Laundry Solution with AI OptimizationLG's new front-loader washer and dryer pair gets laundry clean and dry without running up the power bill; the washer boasting an A-40 percent energy rating1 and the dryer a A+++-20 percent rating.2 The advanced washer promotes wardrobe and environmental sustainability with LG's AI Wash, which intelligently selects the optimal wash cycle to provide 10 percent more fabric protection and help extend the lifespan of clothing.3 It even…
PR Newswire
28/08/2023

Mandatory notification of trade in Vistin Pharma ASA

Ferncliff Listed DAI AS has on 25 August 2023 purchased 200,000 shares in Vistin Pharma ASA at NOK 21 per share. After the transaction Ferncliff Listed DAI AS has a holding of 1,234,280 shares, corresponding to 2,78% ownership. Ferncliff Listed DAI AS is closely associated with board member Øystein Stray Spetalen. Attachment 20230825_Notification of trade_Ferncliff i Vistin
Nasdaq GlobeNewswire
26/08/2023

Innocan Pharma Reports Q2 2023 Results Including US$2.706M Increase in Revenues…

Financial highlights for the second quarter of 2023: Financial highlights for the second quarter of 2023: For a comprehensive understanding of Innocan's consolidated financial statements and related management's discussion and analysis for the three and six months period endedJune 30, 2023, please visit the Company's profile atwww.sedar.com. About Innocan Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness...
PR Newswire
25/08/2023

Information on the Total Number of Voting Rights (Denominator) following…

Regulated Information - Denominator Atlas Special Opportunities, LLChas converted 8convertible bonds in Oxurion resulting in a EUR 200 ,000capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5billion.Leuven, BELGIUM ,Boston, MA, US ...
Nasdaq GlobeNewswire
25/08/2023
Altri  Comunicati